Partners:




FOR IMMEDIATE RELEASE


International Therapeutics, Inc. (ITI) announces the selection of Seattle Biomedical Research Institute (SBRI) as the recipient of the annual “Glenn Kawasaki Humanitarian Award.”

Seattle, WA- November 5, 2002: International Therapeutics, Inc. (ITI) announces the selection of Seattle Biomedical Research Institute (SBRI) as the recipient of the annual “Glenn Kawasaki Humanitarian Award.” The $10,000 award recognizes individuals or institutions for accomplishments in the social, scientific, or medical arenas of human disease management. “SBRI is extremely honored by ITI’s award,” said Kenneth D. Stuart, Ph.D., president and director of SBRI. “SBRI’s research seeks solutions to the diseases that ravage millions of lives each year. We seek to conduct great science in pursuit of a vision of healthy people, thriving communities and stable nations.” Glenn Kawasaki, founder and president of ITI added, “Scientists at SBRI have established preeminence in the field of infectious disease research and education and empowerment in Third World countries, as well as outreach programs locally.”

For more than 25 years, Seattle Biomedical Research Institute (SBRI) researchers have harnessed innovative science and the latest technologies to tackle some of the world’s deadliest killers, including malaria, HIV/AIDS and tuberculosis. SBRI has established a world-wide reputation for its infectious disease research focused on disease treatment and vaccine development. More information about SBRI can be found at
www.sbri.org

International Therapeutics, Inc. (ITI) is a privately held Seattle biotechnology company dedicated to the discovery and development of novel anti-viral therapies. The present focus of the Company is to identify new, safe and effective ways to combat HIV, a virus infecting over 40 million people worldwide. For more information, visit
www.internationaltherapeutics.com




Back